ELISA News and Research

RSS
Recombinant fragment of the lectin-binding region of Gal-3BP stimulates the expression of IL-6 in SARS-CoV-2 sensitive cells

Recombinant fragment of the lectin-binding region of Gal-3BP stimulates the expression of IL-6 in SARS-CoV-2 sensitive cells

5 Apr 2022
Prior COVID vaccination induces a more robust antibody response to Omicron

Prior COVID vaccination induces a more robust antibody response to Omicron

5 Apr 2022
Magnitude and durability of SARS-CoV-2 S-binding antibody titers in the pre-variant era among healthcare workers in NYC

Magnitude and durability of SARS-CoV-2 S-binding antibody titers in the pre-variant era among healthcare workers in NYC

4 Apr 2022
Study shows SARS-CoV-2 antibodies persist for one-year post-infection with protection from other variants

Study shows SARS-CoV-2 antibodies persist for one-year post-infection with protection from other variants

4 Apr 2022
Researchers explore a novel method to isolate monoclonal antibodies from COVID-19 convalescents infected with SARS-CoV-2 variants

Researchers explore a novel method to isolate monoclonal antibodies from COVID-19 convalescents infected with SARS-CoV-2 variants

1 Apr 2022
Study identifies a new class of monoclonal antibodies that neutralize both alpha and beta coronaviruses

Study identifies a new class of monoclonal antibodies that neutralize both alpha and beta coronaviruses

1 Apr 2022
Mosaic-8 RBD-nanoparticles show promise as a vaccine candidate for SARS-CoV-2 and potential sarbecoviruses spillovers

Mosaic-8 RBD-nanoparticles show promise as a vaccine candidate for SARS-CoV-2 and potential sarbecoviruses spillovers

31 Mar 2022
Messenger ribonucleic acid boosters shown to be effective against Omicron infections in mice

Messenger ribonucleic acid boosters shown to be effective against Omicron infections in mice

31 Mar 2022
Common coronavirus infections don't generate antibodies that effectively cross-react with SARS-CoV-2

Common coronavirus infections don't generate antibodies that effectively cross-react with SARS-CoV-2

30 Mar 2022
Divalent SARS-CoV-2 fusion vaccine found to be effective in mice

Divalent SARS-CoV-2 fusion vaccine found to be effective in mice

30 Mar 2022
Engineering rotavirus-based vaccine vectors expressing SARS-CoV-2 spike epitopes

Engineering rotavirus-based vaccine vectors expressing SARS-CoV-2 spike epitopes

30 Mar 2022
A ferritin nanoparticle candidate vaccine for COVID

A ferritin nanoparticle candidate vaccine for COVID

30 Mar 2022
Evaluating serological responses to repeated COVID-19 vaccination in kidney transplant recipients

Evaluating serological responses to repeated COVID-19 vaccination in kidney transplant recipients

29 Mar 2022
Study investigates room-temperature stable, self-amplifying RNA vaccine against SARS-CoV-2

Study investigates room-temperature stable, self-amplifying RNA vaccine against SARS-CoV-2

28 Mar 2022
Durability and functionality of the humoral and T-cell response to SARS-CoV-2 and its variants in recovered patients

Durability and functionality of the humoral and T-cell response to SARS-CoV-2 and its variants in recovered patients

28 Mar 2022
SARS-CoV-2 antibodies in breast milk remain after Holder pasteurization

SARS-CoV-2 antibodies in breast milk remain after Holder pasteurization

27 Mar 2022
UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

UB-612 vaccine booster found to elicit high neutralizing antibody levels against SARS-CoV-2 Omicron

24 Mar 2022
Researchers investigate Galectin-9 as a new treatment target for COVID-19

Researchers investigate Galectin-9 as a new treatment target for COVID-19

23 Mar 2022
Study confirms no preexisting B-cell immunity against SARS-CoV-2 in pre-pandemic samples

Study confirms no preexisting B-cell immunity against SARS-CoV-2 in pre-pandemic samples

23 Mar 2022
Study discovers potent and selective human monoclonal antibodies against Omicron variant of SARS-CoV-2

Study discovers potent and selective human monoclonal antibodies against Omicron variant of SARS-CoV-2

23 Mar 2022

Terms

While we only use edited and approved content for Azthena answers, it may on occasions provide incorrect responses. Please confirm any data provided with the related suppliers or authors. We do not provide medical advice, if you search for medical information you must always consult a medical professional before acting on any information provided.

Your questions, but not your email details will be shared with OpenAI and retained for 30 days in accordance with their privacy principles.

Please do not ask questions that use sensitive or confidential information.

Read the full Terms & Conditions.

Provide Feedback